1. Academic Validation
  2. α-Synuclein interferes with the ESCRT-III complex contributing to the pathogenesis of Lewy body disease

α-Synuclein interferes with the ESCRT-III complex contributing to the pathogenesis of Lewy body disease

  • Hum Mol Genet. 2016 Mar 15;25(6):1100-15. doi: 10.1093/hmg/ddv633.
Brian Spencer 1 Changyoun Kim 2 Tania Gonzalez 1 Alejandro Bisquertt 1 Christina Patrick 1 Edward Rockenstein 1 Anthony Adame 1 Seung-Jae Lee 3 Paula Desplats 1 Eliezer Masliah 4
Affiliations

Affiliations

  • 1 Department of Neuroscience and.
  • 2 Department of Neuroscience and Department of Medicine, College of Medicine, Seoul National University, Seoul 110-799, Korea.
  • 3 Department of Medicine, College of Medicine, Seoul National University, Seoul 110-799, Korea.
  • 4 Department of Neuroscience and Department of Pathology, University of California, San Diego, San Diego, CA 92103, USA and [email protected].
Abstract

α-synuclein (α-syn) has been implicated in neurological disorders with parkinsonism, including Parkinson's disease and Dementia with Lewy body. Recent studies have shown α-syn oligomers released from neurons can propagate from cell-to-cell in a prion-like fashion exacerbating neurodegeneration. In this study, we examined the role of the endosomal sorting complex required for transport (ESCRT) pathway on the propagation of α-syn. α-syn, which is transported via the ESCRT pathway through multivesicular bodies for degradation, can also target the degradation of the ESCRT protein-charged multivesicular body protein (CHMP2B), thus generating a roadblock of endocytosed α-syn. Disruption of the ESCRT transport system also resulted in increased exocytosis of α-syn thus potentially increasing cell-to-cell propagation of synuclein. Conversely, delivery of a lentiviral vector overexpressing CHMP2B rescued the neurodegeneration in α-syn transgenic mice. Better understanding of the mechanisms of intracellular trafficking of α-syn might be important for understanding the pathogenesis and developing new treatments for synucleinopathies.

Figures